Does Amlodipine Increase Your Risk of Cancer?

The best available evidence, drawn from large randomized trials involving hundreds of thousands of people, does not show that amlodipine meaningfully increases your risk of developing cancer. A persistent statistical hint in some analyses of calcium channel blockers as a class has kept the question alive in research circles since the mid-1990s, but this signal is small, inconsistent across study designs, and absent for most specific cancer types. The story is more nuanced than a flat “no,” though, and understanding where the concern came from and what the data actually show is worth your time if you take this drug every day.

How the Concern Started

The worry about calcium channel blockers and cancer dates back to the mid-1990s, when researchers proposed a biological mechanism that sounded alarming on paper. The idea was that these drugs might interfere with apoptosis, the process your body uses to destroy damaged or abnormal cells before they can become cancerous. If a drug suppressed that self-destruct signal, the reasoning went, it could allow precancerous cells to survive and proliferate.

Early observational studies seemed to support the hypothesis. A 1996 study published in The Lancet examined whether long-term calcium channel blocker use was associated with increased cancer risk, framing the concern around apoptosis disruption.¹ A follow-up paper in Hypertension in 1997 went further, suggesting that users might face increased risk for cancer in general and colon cancer specifically.² These findings generated real alarm among patients and clinicians.

But there was a catch. The proposed mechanism had not shown up in the extensive preclinical testing that calcium channel blockers underwent before approval. Animal studies hadn’t revealed cancer-promoting effects. A review in the Journal of the American College of Cardiology noted this disconnect directly, pointing out that while the apoptosis hypothesis was biologically plausible, it lacked support from the preclinical record.³ What followed was decades of increasingly rigorous study designed to settle the question.

What the Largest Clinical Studies Found

The most authoritative data comes from a large individual-participant meta-analysis published in The Lancet Oncology. Researchers pooled data from 33 randomized clinical trials and tracked over 15,000 cancer diagnoses across a median follow-up of about four years. When calcium channel blockers were compared head-to-head against other blood pressure drugs, there was a small statistical signal: a roughly 6% higher relative rate of cancer diagnosis. But when calcium channel blockers were compared against placebo using a network analysis, the signal vanished. The authors concluded there was “no consistent evidence” that blood pressure medications, including calcium channel blockers, affected cancer risk, though they noted that the data for calcium channel blockers specifically couldn’t entirely rule out a small excess.⁴

An earlier network meta-analysis of over 324,000 participants from randomized trials had reached a similar conclusion. It found no difference in cancer risk or cancer-related deaths for calcium channel blockers compared to placebo, and a trial sequential analysis suggested that even a 5 to 10 percent relative increase in risk could be ruled out with reasonable confidence.⁵

Then there is ALLHAT, one of the largest and longest-running blood pressure trials ever conducted. Post-trial follow-up data covering 18 years found that the cumulative cancer incidence was essentially identical across the three drugs studied: about 24% for chlorthalidone (a diuretic), about 23% for amlodipine, and about 25% for lisinopril (an ACE inhibitor). There were no statistically significant differences among the three groups.⁶ Eighteen years of follow-up is a long window, and the fact that amlodipine didn’t separate from its comparators is reassuring.

Why a Small Signal Keeps Appearing in Some Analyses

You might wonder why, if the overall risk is essentially zero, certain studies keep finding that borderline 6% figure for calcium channel blockers. The answer lies partly in how clinical trials are structured and partly in the limitations of observational data.

When drugs are compared against each other rather than against a placebo, small differences in cancer rates can reflect characteristics of the comparison group rather than true harm from the drug being tested. If ACE inhibitors or ARBs happen to have a very slight protective effect against cancer (something a few studies have tentatively suggested), then calcium channel blockers would look slightly worse by comparison even if they have no effect at all. The Lancet Oncology analysis showed exactly this pattern: the small excess for calcium channel blockers appeared only when they were compared to other active drugs, not when compared to placebo.⁴

Observational studies have additional problems. People who are prescribed calcium channel blockers may differ systematically from those prescribed other drugs. They tend to be older, may have more resistant hypertension, and often have more comorbidities. Even after statistical adjustment for known risk factors, residual confounding can create phantom associations. Researchers studying breast cancer risk with calcium channel blockers, for example, have had to carefully lag exposure windows and control for reverse causality, where undiagnosed cancer might have prompted a medication change before the diagnosis was recorded.⁷

Breast Cancer, Prostate Cancer, and Colorectal Cancer

When researchers have looked at specific cancer types, the results have been largely reassuring. Breast cancer has drawn particular scrutiny because a few earlier studies raised concerns. But a large population-based case-control study of women over 55 found no elevated breast cancer risk associated with calcium channel blocker use compared to other antihypertensive drugs.⁸ A separate study in the American Journal of Epidemiology specifically examined long-term use spanning up to 12 years and came to the same conclusion: among older women with high blood pressure, prolonged calcium channel blocker use did not increase breast cancer risk.⁹

The prostate cancer data tells a similar story. A study estimating the relative risk of prostate cancer with any calcium channel blocker use found a risk of 1.2, which was not statistically significant. There was no trend toward higher risk with longer duration of use, either overall or in subgroups of men with prostate symptoms.¹⁰ A Canadian case-control study confirmed that calcium channel blockers did not appear to influence prostate cancer risk.¹¹

Colorectal cancer has also been investigated. A large prospective cohort study using both new-user and prevalent-user designs found no association between calcium channel blocker use and colorectal cancer risk or mortality.¹² One study did observe that colorectal cancer patients who used calcium channel blockers had a somewhat higher rate of developing a second unrelated cancer, but this finding lost statistical significance once multiple factors were accounted for.¹³ In short, the colorectal evidence is not zero, but it isn’t robust enough to change clinical practice.

Kidney Cancer Stands Out

The one cancer type where the data is more concerning is kidney cancer. A large propensity-score-matched cohort study compared people with hypertension taking different drug classes and found that those on dihydropyridine calcium channel blockers, the subclass that includes amlodipine, had a roughly 29% higher rate of kidney cancer compared to those on ACE inhibitors. When compared to people on ARBs, the increase was about 17%. Non-dihydropyridine calcium channel blockers like diltiazem and verapamil did not show this association.¹⁴

This is an observational finding, not proof of causation, and it carries the same confounding caveats described above. But the fact that the signal appeared specifically with dihydropyridine drugs and not with other calcium channel blockers is interesting. Dihydropyridines act primarily on blood vessels and have particularly strong effects on kidney blood flow, which could theoretically influence kidney tissue in ways other calcium channel blockers do not. Whether this finding holds up in future randomized data remains to be seen, and it has not led to regulatory warnings or changes in prescribing guidelines. Still, it is the most notable site-specific signal in the current literature.

Does Taking Amlodipine for Longer Change the Picture?

Duration of use matters to anyone taking a daily medication for years or decades, and a few studies have examined whether cancer risk grows with longer exposure to calcium channel blockers. A large population-based study tracked cancer occurrence over extended follow-up and found a trend toward a modest, progressive increase in risk for calcium channel blockers specifically with exposure durations longer than four years.¹⁵ No such consistent trend was seen for ACE inhibitors, ARBs, or thiazide diuretics in the same cohort.

This is worth noting, but context is essential. The ALLHAT data, which followed amlodipine users for 18 years, found no separation in cancer rates from other drug groups over that long window. The breast cancer studies looking at up to 12 years of use found nothing. When a trend shows up in one study design but not in others with longer observation periods and randomized allocation, the trend is more likely to reflect unmeasured confounding or chance than a real biological signal. Researchers flagged wide confidence intervals with longer exposures, meaning the estimates were imprecise, especially when the number of patients with very long use was relatively small.

Lab Research Suggests Amlodipine May Fight Cancer Cells

In an ironic twist, laboratory research has found that amlodipine can actually kill cancer cells in a dish. A study using two types of human breast cancer cells showed that amlodipine significantly inhibited their growth in a dose-dependent manner, suppressed colony formation, and triggered markers of apoptosis, the same cell-death process that 1990s researchers worried amlodipine might inhibit.¹⁶ Rather than blocking the self-destruct signal, amlodipine appeared to enhance it in these cancer cells.

Lab-dish findings do not translate directly to human bodies, and the concentrations used in these experiments are typically much higher than what circulates in your blood when you take a standard dose. But the results are a useful corrective to the simplistic narrative that calcium channel blockers uniformly promote cancer growth. The biology appears to be more complex than the original hypothesis suggested, with different cell types responding differently and the drug’s effects depending on the specific signaling pathways involved. Research on amlodipine’s action in vascular smooth muscle cells has shown that it affects calcium signaling through at least two distinct mechanisms depending on what stimulus the cell receives.¹⁷ Cancer biology is likely to be at least as context-dependent.

Photosensitivity and Skin Cancer

A separate thread of concern involves photosensitivity. Some blood pressure medications, particularly hydrochlorothiazide, are well-established photosensitizers that can increase skin cancer risk with prolonged sun exposure. Amlodipine is not in that category, but it has appeared alongside photosensitizing drugs in case reports. One report described a patient who developed a phototoxic skin reaction and melanoma in situ while taking a combination of antihypertensives that included amlodipine alongside hydrochlorothiazide and other drugs.¹⁸

A single case report is the weakest form of evidence, and this patient was on multiple drugs simultaneously, making it impossible to attribute the skin findings to amlodipine specifically. Hydrochlorothiazide alone has a much stronger evidence base linking it to skin cancer. But if you take amlodipine in combination with a thiazide diuretic and spend significant time in the sun, the photosensitivity concern belongs to the thiazide component of your regimen, not the amlodipine.

How Amlodipine Compares to Other Blood Pressure Drugs

If you are weighing cancer risk as a factor in choosing a blood pressure medication, the honest answer is that no major class of antihypertensive drug has been convincingly linked to cancer in randomized trial data. The earlier network meta-analysis of over 324,000 participants found that cancer rates were nearly identical across all drug classes and indistinguishable from placebo. The proportion of participants who developed cancer ranged from about 1.95% to 2.11% across categories, with calcium channel blockers at 2.11% and placebo at 2.02%, a difference that was not statistically significant.⁵ Cancer-related mortality showed the same pattern of no meaningful differences.

The individual-participant-data meta-analysis confirmed this for the overall comparison against placebo. The only hint of a signal emerged in the head-to-head comparison of calcium channel blockers against other active drugs, and as discussed, this could reflect mild protective effects from the comparator drugs rather than harm from calcium channel blockers. The practical implication is that switching from amlodipine to an ACE inhibitor or ARB solely because of cancer fear is not well-supported by the evidence. If your blood pressure is well controlled on amlodipine and you tolerate it, the cardiovascular benefits of staying on effective treatment almost certainly outweigh a hypothetical cancer risk that decades of research have failed to confirm.

The Amlodipine-Specific Question

Most of the research discussed above looks at calcium channel blockers as a class rather than amlodipine in isolation. This matters because calcium channel blockers include several structurally different drugs: dihydropyridines like amlodipine and nifedipine, and non-dihydropyridines like diltiazem and verapamil. These subclasses work through somewhat different mechanisms and have different side-effect profiles. The kidney cancer study noted earlier found a signal only with dihydropyridines and not with non-dihydropyridines, suggesting that lumping all calcium channel blockers together may obscure subclass-specific differences.

Amlodipine is by far the most widely prescribed drug in its class, which means it is also the most studied. The ALLHAT trial specifically randomized patients to amlodipine and tracked them for nearly two decades. Its clean bill of health applies to amlodipine specifically, not just to calcium channel blockers in general. For the broader meta-analyses that pool across the whole drug class, amlodipine likely contributes a large share of the data, making it reasonable to apply those conclusions to the drug itself. Whether less commonly used dihydropyridines like felodipine or nicardipine carry different risk profiles is harder to say, simply because fewer people take them and the data are thinner.

What Researchers Are Still Watching

The kidney cancer signal from dihydropyridine calcium channel blockers is the finding that most warrants continued surveillance. It appeared in a well-designed propensity-matched study and showed a consistent pattern across multiple comparisons with other drug classes.¹⁴ It also has at least a plausible mechanism through the strong effects of dihydropyridines on renal blood flow. This is not something to panic about: kidney cancer is relatively rare, and even a 29% relative increase on a rare baseline means a very small absolute increase. But it is the kind of finding that will prompt further investigation.

The duration question also remains open. If there is a real but tiny effect of calcium channel blockers on cancer risk, it would most plausibly emerge with very long exposure, and very long exposure data is inherently harder to collect cleanly. Studies relying on administrative databases can track people for decades but struggle with confounding, medication switching, and incomplete cancer ascertainment. Randomized trials provide cleaner data but rarely last more than five to ten years. The ALLHAT extension to 18 years is the closest thing to a gold standard on this, and its finding of no difference for amlodipine is the single most reassuring data point for long-term users.